Armo BioSciences is a late-stage immuno-oncology company developing a pipeline of proprietary products that activate patients' immune systems to recognize and eradicate tumors. Its lead candidate, AM0010 (pegilodecakin), stimulates survival, expansion and cytotoxic activity of CD8+ T cells. AM0010 has received Orphan Drug designation from the FDA and European Commission for pancreatic cancer and FDA Fast Track designation in combination with FOLFOX as second-line therapy for pancreatic cancer. The company is advancing additional immunotherapy candidates including an anti-PD-1 monoclonal antibody slated to enter the clinic in 2018 and an anti-LAG-3 program in preclinical development. Armo plans to use recent financing to initiate phase 2/3 studies of AM0010 in non-small cell lung cancer and renal cell carcinoma and to support an ongoing pivotal phase 3 trial in advanced pancreatic cancer. Armo BioSciences is a clinical-stage biotechnology company focused on developing immunotherapies for multiple oncology indications. Its lead product candidate is AM0010, an immunotherapy that has shown activity as a monotherapy and in combination with anti-PD-1 agents. Clinical signals have been observed in immune-sensitive tumors including melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC), as well as colorectal (CRC) and pancreatic (PDAC) cancers. The company’s pipeline also includes cytokines and an anti‑PD‑1 monoclonal antibody checkpoint inhibitor. Armo plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors. The company is led by President and CEO Peter Van Vlasselaer, Ph.D. ARMO BioSciences is a Redwood City, CA–based clinical-stage biotechnology company founded in 2012 and led by president and CEO Peter Van Vlasselaer, Ph.D. The company focuses on developing immunotherapies for cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. Its lead program is AM0010 (PEG-rHuIL-10), a PEGylated recombinant human interleukin-10 designed to directly activate tumor-specific CD8+ killer T lymphocytes. ARMO intends to use the Series B proceeds to complete a Phase 1 clinical study of AM0010 in advanced solid tumors. It planned to begin patient enrollment in the fifth dose-escalation cohort that month. The financing is aimed at advancing the AM0010 program through the current dose-escalation stage.

Total raised

$147M

Funding rounds

3

Latest round

Series C

Latest activity

Aug 2017